Please wait while the formulary information is being retrieved.
ARNUITY ELLIPTA (FLUTICASONE FUROATE)
- Maintenance therapy for asthma
100 mcg/actuation powder for inhalation
- Inhale 1 puff (100 mcg) by inhalation route once daily at the same time each day
200 mcg/actuation powder for inhalation
- Inhale 1 puff (200 mcg) by inhalation route once daily at the same time each day
50 mcg/actuation powder for inhalation
- Dosage information is not available
Maintenance therapy for asthma
- Inhale 1 puff (100 mcg) by inhalation route once daily at the same time each day
- Inhale 1 puff (200 mcg) by inhalation route once daily at the same time each day
- natalizumab
- Tysabri
Contraindicated
- boceprevir
- elvitegr-cobicist-emtric-tenof
- Incivek
- Kaletra
- Korlym
- lopinavir-ritonavir
- Mifeprex
- mifepristone
- Norvir
- Norvir Soft Gelatin
- ritonavir
- Stribild
- telaprevir
- Victrelis
Severe
Moderate
- amoxicil-clarithromy-lansopraz
- Avelox
- Avelox Abc Pack
- Avelox In Nacl (iso-osmotic)
- Biaxin
- Biaxin Xl
- Biaxin Xl Pak
- Cipro
- Cipro In D5W
- Cipro Xr
- ciprofloxacin
- ciprofloxacin (mixture)
- ciprofloxacin in D5W
- clarithromycin
- Erythrocin
- erythromycin
- erythromycin-sulfisoxazole
- itraconazole
- ketoconazole
- Levaquin
- Levaquin In 5 % Dextrose
- levofloxacin
- levofloxacin in D5W
- moxifloxacin
- moxifloxacin in NaCl (iso-osm)
- norfloxacin
- Noroxin
- ofloxacin
- Omeclamox-pak
- omeprazole-clarith-amoxicillin
- Onmel
- Prevpac
- Sporanox
- Sporanox Pulsepak
- None
Contraindicated
- Active tuberculosis
- Ocular herpes simplex
- Parasitic infection
Severe
Moderate
- Cataracts
- Hypothalamic-pituitary insufficiency
- Open angle glaucoma
- Oral candidiasis
- Osteopenia
- Osteoporosis
ARNUITY ELLIPTA (FLUTICASONE FUROATE)
- Maintenance therapy for asthma
- Bronchitis
- Cough
- Headache disorder
- Myalgias
- Oral candidiasis
- Pharyngeal candidiasis
- Pharyngitis
- Sinusitis
- Upper respiratory infection
More Frequent
Severe
Less Severe
- None
- Voice change
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Aggressive behavior
- Anaphylaxis
- Angioedema
- Cataracts
- Central serous chorioretinopathy
- Esophageal candidiasis
- Glaucoma
- Hypercortisolism
- Hyperglycemia
- Hypersensitivity angiitis
- Immunosuppression
- Osteopenia
- Osteoporosis
- Paradoxical bronchospasm
- Pneumonia
- Skin and skin structure infection
- Skin rash
- Urinary tract infection
- Urticaria
Less Severe
- Agitation
- Arthralgias
- Blurred vision
- Dental caries
- Dental discoloration
- Depression
- Diarrhea
- Dizziness
- Dyspepsia
- Dyspnea
- Ecchymosis
- Eosinophilia
- Facial edema
- Fatigue
- Fever
- Hyperkinesis
- Irritability
- Laryngitis
- Muscle rigidity
- Nausea
- Pruritus of skin
- Rhinitis
- Rhinorrhea
- Sore throat
- Symptoms of anxiety
- Viral infection
- Vomiting
- Weight gain
- Xerostomia
Contraindicated
None
Severe Precaution
Fluticasone (50 mcg blister)
Risk of decreased growth velocity. Safety and efficacy not established age < 5 years.
Potential risk of decreased growth velocity. Safety and efficacy not established age < 12 years.
- 1 Day – 5 Years
- Risk of decreased growth velocity. Safety and efficacy not established age < 5 years.
- 1 Day – 12 Years
- Risk of decreased growth velocity. Safety and efficacy not established age < 5 years.
Fluticasone (Inhal blister, pwd)
Risk of decreased growth velocity. Safety and efficacy not established age < 5 years.
Potential risk of decreased growth velocity. Safety and efficacy not established age < 12 years.
- 1 Day – 5 Years
- Potential risk of decreased growth velocity. Safety and efficacy not established age < 12 years.
- 1 Day – 12 Years
- Potential risk of decreased growth velocity. Safety and efficacy not established age < 12 years.
Management or Monitoring Precaution
Fluticasone (50 mcg blister)
Risk of decreased growth velocity. Titrate to lowest effective dose and monitor growth
- 5 Years – 18 Years
- Risk of decreased growth velocity. Titrate to lowest effective dose and monitor growth
- 12 Years – 18 Years
- Risk of decreased growth velocity. Titrate to lowest effective dose and monitor growth
Fluticasone (Select)
Risk of decreased growth velocity. Titrate to lowest effective dose and monitor growth
- 5 Years – 18 Years
- Risk of decreased growth velocity. Titrate to lowest effective dose and monitor growth
- 12 Years – 18 Years
- Risk of decreased growth velocity. Titrate to lowest effective dose and monitor growth
Fluticasone (inhal)
- Severity Level:
2
- Additional Notes: Current evidence supports use of inhaled corticosteroids for asthma tx in preg
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Fluticasone (inhal, Nasal)
Systemic products excreted in rats; caution advised with nasal administration
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Systemic products excreted in rats; caution advised with nasal administration |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Fluticasone (inh)
Musculoskeletal-Use with caution in patients with osteoporosis. Decreases in bone mineral density (BMD) has been observed with long-term administration of products containing inhaled corticosteroids.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | N | Y |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Maintenance therapy for asthma | |
| J45 | Asthma |
| J45.2 | Mild intermittent asthma |
| J45.20 | Mild intermittent asthma, uncomplicated |
| J45.3 | Mild persistent asthma |
| J45.30 | Mild persistent asthma, uncomplicated |
| J45.4 | Moderate persistent asthma |
| J45.40 | Moderate persistent asthma, uncomplicated |
| J45.5 | Severe persistent asthma |
| J45.50 | Severe persistent asthma, uncomplicated |
| J45.9 | Other and unspecified asthma |
| J45.90 | Unspecified asthma |
| J45.909 | Unspecified asthma, uncomplicated |
| 0-9 | A-Z |
|---|---|
| J45 | Asthma |
| J45.2 | Mild intermittent asthma |
| J45.20 | Mild intermittent asthma, uncomplicated |
| J45.3 | Mild persistent asthma |
| J45.30 | Mild persistent asthma, uncomplicated |
| J45.4 | Moderate persistent asthma |
| J45.40 | Moderate persistent asthma, uncomplicated |
| J45.5 | Severe persistent asthma |
| J45.50 | Severe persistent asthma, uncomplicated |
| J45.9 | Other and unspecified asthma |
| J45.90 | Unspecified asthma |
| J45.909 | Unspecified asthma, uncomplicated |
Formulary Reference Tool